分享到:

解密幕后“药神”FDA

走进门时,是互不相识、毫无关联的陌生人;当审核过后,走出FDA的大门,审查成员和药企却成了利益攸关的双方。近  (本文共3页) 阅读全文>>

权威出处: 北京商报2018-07-12
《China Chemical Reporter》2009年27期
China Chemical Reporter

AstraZeneca China Holds Ground-breaking Ceremony for Zhangjiang Site

On September 9th, 2009, AstraZeneca Chinaheld the ground-breaking ceremony for its newsite in Zhangjiang High-Tech Park, which isalso known as China's medicine valley. Onceth...  (本文共1页) 阅读全文>>

《中国药理学与毒理学杂志》2013年03期
中国药理学与毒理学杂志

Validation and implementation of Provantis ~Computer System in GLP facility

CDSER(Centre for Drug Safety Evaluation and Research)perform GLP Toxicology studies according toSFDA,FDA,Japan and OECD guidelines.To help achieve this,the Provantis Computerised System for Toxicology DataManagement,Collection and Reporting has been implemented to manage the data electronically since 2011 at CDSER.There are some experiences from us:①A hosted environment is used and provided by the vendor,Instem,inclu...  (本文共1页) 阅读全文>>

《国外医学情报》2006年08期
国外医学情报

欧洲卒中会议推出全球最全面的卒中经历调查计划

AstraZeneca(阿斯利康)与SAFE(欧洲卒中联盟)近日宣布将推出最全面的全球卒中调查。这项在欧洲卒...  (本文共2页) 阅读全文>>

《China Today》2006年02期
China Today

Foreign Pharmaceutical R&D Centers Come to China

THOUGH China has madeits own medicines for mil-lennia, fast-acting Westerntreatments are becomingpopul...  (本文共2页)

《精细与专用化学品》2003年21期
精细与专用化学品

医药、兽药

AstraZeneca在印建药物研发中心及制药厂AstraZeneca公司在印度的班加罗尔 (Banga lore)投资 4 0...  (本文共2页) 阅读全文>>